1. Share Prices

  2. Hvivo PLC (HVO)

28.89p+0.39 (+1.37%)25 Apr 2024, 10:00
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Hvivo PLC Fundamentals

Company NameHvivo PLCLast Updated2024-04-25
IndustryBiotechnologySectorHealthcare
Shares in Issue680.372 mMarket Cap£196.56 m
PE Ratio12.13Dividend per Share0
Dividend Yield0.7Dividend Cover0
EPS£0.02EPS Growth (%)2.28
PEG0DPS Growth (%)0
Debt Ratio0.1506Debt Equity Ratio0.3543
Asset Equity Ratio2.4246Cash Equity Ratio1.0771
Quick Ratio1.4262Current Ratio1.48
Price To Book Value5.6497ROCE0

Hvivo PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Prelim2024-04-182024-05-20GBP0.0020

Hvivo PLC Company Financials

Assets202320222021
Tangible Assets£20.04 m£3.12 m£3.71 m
Intangible Assets£5.67 m£6.02 m£6.22 m
Investments00£7.00 m
Total Fixed Assets£31.22 m£9.15 m£16.94 m
Stocks£426,000.00£499,000.00£659,000.00
Debtors£13.20 m£12.30 m£8.09 m
Cash & Equivalents£36.97 m£28.44 m£15.69 m
Other Assets£5.52 m00
Total Assets£83.23 m£51.38 m£42.27 m
Liabilities202320222021
Creditors within 1 year£35.18 m£29.77 m£20.69 m
Creditors after 1 year£13.72 m£1.40 m£903,000.00
Other Liabilities000
Total Liabilities£48.90 m£31.16 m£21.59 m
Net assets£34.33 m£20.22 m£20.68 m
Equity202320222021
Called up share capital£680,000.00£671,000.00£671,000.00
Share Premium£516,000.00£4,000.00£1,000.00
Profit / Loss£11.15 m-£365,000.00£277,000.00
Other Equity£34.33 m£20.22 m£20.68 m
Preference & Minorities000
Total Capital Employed£34.33 m£20.22 m£20.68 m
Ratios202320222021
Debt Ratio£0.26£0.04£0.04
Debt-to-Equity£0.35£0.04£0.04
Assets / Equity2.42462.42462.4246
Cash / Equity1.07711.07711.0771
EPS£0.02£0.01£-0.00
Cash Flow202320222021
Cash from operating activities£17.24 m£15.98 m£765,000.00
Cashflow before financing£13.72 m£14.15 m-£2.76 m
Increase in Cash£8.54 m£12.79 m-£3.50 m
Income202320222021
Turnover£56.04 m£48.48 m£36.86 m
Cost of sales000
Gross Profit000
Operating Profit£10.10 m£6.02 m£590,000.00
Pre-Tax profit£11.15 m-£365,000.00£277,000.00

Hvivo PLC Company Background

SectorHealthcare
ActivitieshVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
Latest Interim Date12 Sep 2023
Latest Fiscal Year End Date9 Apr 2024

Hvivo PLC Directors

AppointedNamePosition
2020-01-20Mr. Michael P Ryan Non-Executive Director,Senior Independent Director
2013-06-18Mr. Adam ReynoldsNon-Executive Director
2014-04-14Mr. Paul Andrew Peter FoulgerExecutive Director,Finance Director and Company Secretary
2016-01-08Mr. David Eric EvansNon-Executive Director,Chairman
2020-07-06Mr. Anthony Francis Richardson Executive Director,Corporate Development Director
2019-06-13Mr. Paul Francis Kennedy Non-Executive Director
2018-12-11Mr. Allan Leigh Wood Executive Director,Chairman
2024-04-15Mr. Cathal Martin FrielNon-Executive Director,Chairman
2019-06-11Ms. Mary Blake Sheahan Non-Executive Director
2017-08-16Ms. Gracielle Anna Maria Beijerbacht-SchutjensExecutive Director,Chief Operating Officer
2018-03-21Mr. Jonathan David HartshornExecutive Director,Chief Financial Officer
2020-05-04Mr. Mark Robert WarneNon-Executive Director
2017-04-06Mr. Kees GroenExecutive Director
2020-01-20Dr. Christian Bernard MillaExecutive Director,Chief Operating Officer
2024-04-15Professor Brendan BuckleyNon-Executive Director
2020-01-20Dr. Maurice Treacy Executive Director
2024-04-15Mr. Yamin Mohammed KhanExecutive Director,Chief Executive Officer
2024-02-15Mr. Stephen PinkertonExecutive Director,Chief Financial Officer

Hvivo PLC Contact Details

Company NamehVIVO PLC
Address1 Berkeley Street, London, W1J 8DJ
Telephone+353 15373269
Websitehttps://www.hvivo.com

Hvivo PLC Advisors

Nominated AdviserCenkos Securities
Phone+44 2073978900
StockbrokerCenkos Securities
Phone+44 2073978900
StockbrokerHybridan LLP
Phone+44 203764 2341
Fax+44 2076001586
BankUlster Bank Group
AuditorJeffreys Henry LLP
Phone+44 2073092222
Fax+44 2073092309
Financial PR AdviserWalbrook PR
Phone+44 2079338780
Fax+44 2079338781
RegistrarS.L.C Registrars Ltd
Phone+44 1903706150
SolicitorBPE Solicitors LLP
Phone+44 1242224433
Fax+44 1242574285

Receive our
daily news email

Subscribe to the latest investing news by entering your email address below

You can opt out at any time.

For five days a week you will get

  • The latest company news
  • Insight into investment trends
  • Round-up of director's buys and sells
  • Articles from Shares magazine
Sharesmagazine cover

Plus more useful investment content and occasional promotional offers.

Shares Magazine Latest Issue Cover
Latest Issue:
25 Apr 2024Subscribe now

Market Overview

UK 350 Risers and Fallers

Risers

CompanyPrice% Chg
Anglo American PLC2,491.0012.97
Inchcape PLC772.007.37
Puretech Health PLC224.005.41
Astrazeneca PLC11,946.005.23
Unilever PLC4,059.795.09
Barclays PLC198.563.88

Fallers

CompanyPrice% Chg
Moonpig Group PLC158.40-10.81
Trainline PLC321.41-6.29
Legal & General Group PLC237.30-4.55
Indivior PLC1,446.00-4.49
Wh Smith PLC1,203.00-4.37
Bakkavor Group PLC118.88-3.35